Crowdonomics
WatchlistPortfolio
All companies
Peptinovo Biopharma logo

Peptinovo Biopharma

Operating

PEPTINOVO BIOPHARMA INC.

Biotech · Ann Arbor, MI

Visit website
Latest valuation
—
No round has disclosed a priced valuation or cap.
Total raised
$2,354,700
Crowd $81K · Private $2.3M · 3 rounds since 2021
Latest share price
$3.3853
Reg CF · Preferred Stock · Mar 2025 offering price

Financials

FY2022–FY2026 (no data for FY2024) · from SEC filings · hover any figure for its source
$2K
−$239K
2022
$2K
−$2.8M
2023
2024no data
$2K
−$4.8M
2025
$3K
−$5.6M
2026
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022 reviewed
FY2023 reviewed
FY2025 unaudited
FY2026 unaudited
Income statement
Revenue
$1,971
$1,545
$2,483
$2,585
Cost of goods sold
$0
$0
$0
$0
Gross margin
100%
100%
100%
100%
Net income
-$239,183
-$2,832,689
-$4,803,155
-$5,603,365
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$59,735
$350,498
$430,647
$137,173
Accounts receivable
$0
$0
$0
$0
Total assets
$1,941,396
$2,243,238
$3,058,495
$1,624,769
Short-term debt
$396,329
$393,309
$1,426,654
$7,954,868
Long-term debt
$742,500
$3,755,900
$2,000,000
$0
Total liabilities
$1,138,829
$4,149,209
$3,426,654
$7,954,868
Other
Headcount
—
5
—
4

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Fundraising history

Reg CF · Preferred Stock · Mar 2025Closedvia Silicon Prairie
Raised $81K / $1.3M
Rule 506(c) · Equity · Sep 2024Closed
Raised $1.3MInvestors 12
Rule 506(b) · SAFE · Jun 2021Closed
Raised $955KInvestors 12

Team

5 people
STEVE TOKARZ
CEO
REYNOLD HOMAN
PRESIDENT AND DIRECTOR
DAVID ROMENSKO
DIRECTOR
FRED BROWN
DIRECTOR
MICHAEL MORTLOCK
PRINCIPAL ACCOUNTING OFFICER

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 1 of 2 annual reports (FY2024–FY2025)

12 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

View all 11 filings on EDGAR
  • Form C-TRSep 3, 20260001868564-26-000008
    EDGAR
  • Form C-ARSep 2, 20260001868564-26-000006
    EDGAR
  • Form C-UAug 31, 20260001868564-26-000004
    EDGAR
  • Form C/AAug 20, 20260001868564-26-000002
    EDGAR
  • Form C/AOct 2, 20250001868564-25-000009
    EDGAR
  • Form C/ASep 4, 20250001868564-25-000005
    EDGAR
  • Form C/AMar 10, 20250001868564-25-000004
    EDGAR
  • Form CMar 5, 20250001868564-25-000002
    EDGAR
Source: SEC EDGARCIK 0001868564DEShare price $3.3853Last synced Aug 17, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.